

1 **Title page**

2 **Full Title**

3 *Shigella sonnei* infection of zebrafish reveals that O-antigen mediates neutrophil tolerance
4 and dysentery incidence

5

6 **Short Title**

7 *S. sonnei* O-antigen and dysentery incidence
8

9 **Authors**

10 Vincenzo Torraca^{1,2}, Myrsini Kaforou³, Jayne Watson⁴, Gina M. Duggan^{1,2}, Hazel Guerrero-
11 Gutierrez¹, Sina Krokowski^{1,2}, Michael Hollinshead⁵, Thomas B. Clarke¹, Rafal J. Mostowy^{6,7},
12 Gillian S. Tomlinson⁸, Vanessa Sancho-Shimizu^{3,9}, Abigail Clements⁴, Serge Mostowy^{1,2*}

13

14 **Affiliations**

15 ¹Section of Microbiology, MRC Centre for Molecular Bacteriology and Infection, Imperial
16 College London, London, UK

17 ²Department of Infection Biology, London School of Hygiene & Tropical Medicine, London, UK

18 ³Department of Paediatrics, Division of Medicine, Imperial College London, London, UK

19 ⁴Faculty of Natural Sciences, Department of Life Sciences, MRC Centre for Molecular
20 Bacteriology and Infection, Imperial College London, London, UK

21 ⁵Division of Virology, Department of Pathology, Cambridge University, Cambridge, UK

22 ⁶Malopolska Centre of Biotechnology, Jagiellonian University, Krakow, Poland

23 ⁷Faculty of Medicine, School of Public Health, Imperial College London, London, UK

24 ⁸Division of Infection and Immunity, University College London, London, UK

25 ⁹Department of Virology, Division of Medicine, Imperial College London, London, UK

26 *Corresponding author: Prof. Serge Mostowy, Department of Infection Biology, London School
27 of Hygiene & Tropical Medicine, Keppel St, London WC1E 7HT UK, phone: +44 (0) 207 927
28 2600, email: serge.mostowy@lshtm.ac.uk.

29

30 **Author contributions**

31 V.T. and S.M. designed the research and analysed the data. V.T., G.M.D., H.G.G., S.K. and
32 M.H. performed experiments. J.W. and A.C. contributed bacterial strains. M.K., G.S.T. and
33 R.J.M. provided supervision and assistance with RNAseq data analysis and presentation.
34 T.B.C. and V.S.S. provided supervision and assistance with neutrophil infection experiments.
35 V.T. and S.M. wrote the manuscript with input from all the authors.

36

37 **Keywords**

38 neutrophils, O-antigen, *Shigella flexneri*, *Shigella sonnei*, zebrafish

39

40

41 **Abstract**

42 *Shigella flexneri* is historically regarded as the primary agent of bacillary dysentery, yet the
43 closely-related *Shigella sonnei* is replacing *S. flexneri*, especially in developing countries. The
44 underlying reasons for this dramatic shift are mostly unknown. Using a zebrafish (*Danio rerio*)
45 model of *Shigella* infection, we discover that *S. sonnei* is more virulent than *S. flexneri* *in vivo*.
46 Whole animal dual-RNAseq and testing of bacterial mutants suggest that *S. sonnei* virulence
47 depends on its O-antigen oligosaccharide (which is unique among *Shigella* species). We show
48 *in vivo* using zebrafish and *ex vivo* using human neutrophils that *S. sonnei* O-antigen can
49 mediate neutrophil tolerance. Consistent with this, we demonstrate that O-antigen enables *S.*
50 *sonnei* to resist phagolysosome acidification and promotes neutrophil cell death. Chemical
51 inhibition or promotion of phagolysosome maturation respectively decreases and increases
52 neutrophil control of *S. sonnei* and zebrafish survival. Strikingly, larvae primed with a sublethal

53 dose of *S. sonnei* are protected against a secondary lethal dose of *S. sonnei* in an O-antigen-
54 dependent manner, indicating that exposure to O-antigen can train the innate immune system
55 against *S. sonnei*. Collectively, these findings reveal O-antigen as an important therapeutic
56 target against bacillary dysentery, and may explain the rapidly increasing *S. sonnei* burden in
57 developing countries.

58

59

60 **Author Summary**

61 *Shigella sonnei* is predominantly responsible for dysentery in developed countries, and is
62 replacing *Shigella flexneri* in areas undergoing economic development and improvements in
63 water quality. Using *Shigella* infection of zebrafish (*in vivo*) and human neutrophils (*in vitro*),
64 we discover that *S. sonnei* is more virulent than *S. flexneri* because of neutrophil tolerance
65 mediated by its O-antigen oligosaccharide acquired from the environmental bacteria
66 *Plesiomonas shigelloides*. To inspire new approaches for *S. sonnei* control, we show that
67 increased phagolysosomal acidification or innate immune training can promote *S. sonnei*
68 clearance by neutrophils *in vivo*. These findings have major implications for our evolutionary
69 understanding of *Shigella*, and may explain why exposure to *P. shigelloides* in low and middle-
70 income countries (LMICs) can protect against dysentery incidence.

71

72

73 **Introduction**

74 *Shigella* is the causative agent of bacillary dysentery (also called shigellosis), resulting from
75 invasion of the intestinal epithelium and leading to ~164,000 deaths annually [1,2]. *Shigella*
76 is also recognised by the World Health Organization as a priority pathogen exhibiting
77 antimicrobial resistance [3,4]. The emergence of multidrug resistant bacteria and the lack
78 of effective vaccines has resulted in a desperate need to understand *Shigella* pathogenesis
79 and identify new approaches for infection control. In the lab, infection with *Shigella flexneri*

80 has been a valuable discovery tool in the field of innate immunity, helping to illuminate the role
81 of neutrophil extracellular traps (NETs) [5], nucleotide-binding oligomerisation domain (NOD)-
82 like receptors (NLRs) [6], bacterial autophagy [7], interferon-inducible guanylate-binding
83 proteins (GBPs) [8,9] and septin-mediated cell-autonomous immunity [10,11] in host
84 defence.

85

86 The genus *Shigella* comprises four different species (*S. flexneri*, *S. sonnei*, *S. boydii*, *S.*
87 *dysenteriae*), although DNA sequencing suggests they evolved from convergent evolution of
88 different founders [12]. The most recent strains of *S. flexneri* emerged from *Escherichia coli*
89 >35,000 years ago [12], while *S. sonnei* (a monoclonal strain) emerged from *E. coli* in central
90 Europe ~500 years ago [13]. *S. flexneri* is historically regarded as the primary agent of
91 dysentery worldwide, yet *S. sonnei* has recently become the most prevalent cause of
92 dysentery in developing countries (i.e., areas undergoing economic development and
93 improvements in water quality) [14,15]. Reasons for this dramatic shift are mostly unknown.
94 Hypotheses include improved water sanitisation leading to reduced cross-immunisation by
95 *Plesiomonas shigelloides* (which carries an O-antigen oligosaccharide identical to *S. sonnei*)
96 [15,16], as well as a type VI secretion system (T6SS)-mediated competitive advantage that *S.*
97 *sonnei* exerts over *S. flexneri* and the Gram-negative gut microbiome for niche occupancy
98 [17].

99

100 Except for non-human primates, there is no mammalian model that fully recapitulates human
101 shigellosis. The zebrafish model is increasingly being used to study human bacterial
102 pathogens *in vivo*, including *S. flexneri* [18,19]. The major pathogenic events that lead to
103 shigellosis in humans (i.e., macrophage cell death, invasion and multiplication within epithelial
104 cells, cell-to-cell spread, inflammatory destruction of the host epithelium) are recapitulated in
105 a zebrafish model of *S. flexneri* infection [20]. Exploiting the optical accessibility of zebrafish
106 larvae, it is possible to spatio-temporally examine the development, coordination and
107 resolution of the innate immune response to *S. flexneri* *in vivo*. As a result, *S. flexneri*-zebrafish

108 infection has been useful to illuminate key roles for bacterial autophagy [21], bacterial
109 predation [22], inflammation [23] and trained innate immunity [24] in host defence *in vivo*.

110

111 How *S. sonnei* infection differs from *S. flexneri* infection is poorly understood, yet clinical
112 management of both infections is the same. Here, we develop a *S. sonnei*-zebrafish infection
113 model and discover that *S. sonnei* is more virulent than *S. flexneri* *in vivo* because of neutrophil
114 tolerance mediated by its O-antigen. We show that increased phagolysosomal acidification or
115 innate immune training can promote *S. sonnei* clearance by neutrophils *in vivo*. These results
116 may inspire new approaches for *S. sonnei* control.

117

118

119 **Results**

120 ***S. sonnei* is more virulent than *S. flexneri* in a zebrafish infection model**

121 To compare the virulence of *S. flexneri* and *S. sonnei* *in vivo*, we injected *S. flexneri* M90T or
122 *S. sonnei* 53G in the hindbrain ventricle (HBV) of zebrafish larvae at 3 days post-fertilisation
123 (dpf). Unexpectedly, *S. sonnei* led to significantly more zebrafish death and higher bacterial
124 burden, as compared to *S. flexneri* (Fig. 1A,B). The majority of larvae inoculated with <600
125 CFU of *S. sonnei* survive, whereas the majority of larvae inoculated with >1500 CFU of *S.*
126 *sonnei* die by 72 hpi (Fig. S1A,B). In agreement with being more virulent, *S. sonnei* infected
127 larvae have significantly increased expression of key inflammatory markers at 6 and 24 hpi,
128 as compared to *S. flexneri* infected larvae (Fig. 1C,D). Moreover, *S. sonnei*, unlike *S. flexneri*,
129 disseminates out of the HBV into the neuronal tube and bloodstream (Fig. 1E,F, Fig. S1C-F).
130 The increased virulence of *S. sonnei* is also observed using an intravenous route of infection
131 (Fig. S1G-H), using human clinical isolates of bacteria (Fig. S1I-J) and when infected larvae
132 are incubated at 28.5°C, 32.5°C or 37°C (Fig. 1A,B, Fig. S1K-N). Therefore, we used *S.*
133 *sonnei* 53G infection of the HBV (incubated at 28.5°C, the standard temperature for zebrafish
134 maintenance) for the rest of our study. Taken together, using multiple infection routes,

135 bacterial strains and temperatures, these data show for the first time that *S. sonnei* is
136 significantly more virulent than *S. flexneri* *in vivo*.

137

138 **Whole animal dual-RNAseq profiling of *S. sonnei* infected larvae**

139 The transcriptional signature of *Shigella* *in vivo* was mostly unknown. We performed whole
140 animal dual-RNAseq profiling of *S. sonnei* infected larvae by isolating whole RNA at 24 hpi
141 and mapping reads to both *Shigella* and zebrafish genomes (**Fig. 2A**). RNA isolated from Log
142 phase ($OD_{600} \sim 0.6$) bacterial culture grown at 28.5°C was used as baseline for the identification
143 of differential expression in the bacterial transcriptome. RNA isolated from PBS-injected larvae
144 was used as baseline for the identification of differential expression in the host transcriptome.
145 Gene count data was obtained for both the host and pathogen, and statistical analysis was
146 performed using DESeq2 (see dedicated section in Materials and Methods). Genes were
147 considered significantly differentially expressed if $\text{Log}_2(\text{FC}) > 1$ or < -1 and the adjusted p
148 value < 0.05 . Principal component analysis (PCA) was employed for *S. sonnei* and larval count
149 data separately, and these plots confirm the clustering between biological replicates according
150 to their state (**Fig. S2A,B**). After performing differential expression analysis between infected
151 and control states, we found 1538 differentially expressed *S. sonnei* genes (representing ~1/3
152 of the *S. sonnei* 53G genome, **Fig. 2B**, see also **Table S1** and **Fig. S2** for in-depth exploration)
153 and 337 differentially expressed zebrafish genes (**Fig. 2C**, see also **Table S2** and **Fig. S2** for
154 in-depth exploration). In the case of *S. sonnei*, 878 genes are significantly upregulated,
155 including genes involved in resistance to stress (i.e. adaptation to acidic environment,
156 metabolism, DNA damage repair; **Fig. 2D**, see also **Fig. S2E,G,J** and **Table S1**). In the case
157 of *S. sonnei*-infected larvae, 283 host genes are significantly upregulated, including
158 inflammatory markers previously tested by qRT-PCR (**Fig. 1C,D**) and other genes involved in
159 innate immune signalling, granulopoiesis/neutrophil chemotaxis and inflammation (**Fig. 2E**,
160 see also **Fig. S2F,H,I,K** and **Table S2**). Consistent with this, enrichment analysis for DNA
161 regulatory elements identified the statistical overrepresentation of immune-related
162 transcription factor binding sites (i.e. Rel/Rela, NfkB2, Stats, Cepbg, Jun, Spi1; **Table S2**).

163 Together, whole animal dual-RNAseq profiling identified novel markers of *S. sonnei* infection
164 and zebrafish host defence, and we generated an open-access resource for their in-depth
165 exploration (raw sequencing data will be uploaded into GEO, the NCBI repository).

166

167 ***S. sonnei* virulence depends on its O-antigen**

168 *S. sonnei* encodes a T6SS and capsule which have been linked to virulence in the murine and
169 rabbit intestine model, respectively (Fig. S3A,B) [17,25]. However, when larvae are infected
170 with a T6SS ($\Delta tssb$) or capsule ($\Delta g4c$) deficient strain, virulence is not significantly reduced
171 as compared to wildtype (WT) bacteria (Fig. S3C,D). We next infected larvae with a phase II
172 *S. sonnei* strain which lacks the pSS virulence plasmid (-pSS *S. sonnei*). Here, ~100% of
173 larvae survive infection (Fig. 3A,B). Consistent with a role in virulence, the *S. sonnei* pSS
174 plasmid (which is unstable and frequently lost in culture [26]) is retained during zebrafish
175 infection at 28.5°C (Fig. S3E). The *S. sonnei* pSS encodes a type III secretion system (T3SS)
176 and the biosynthesis machinery for an O-antigen oligosaccharide (O-Ag) non-homologous to
177 those encoded by other *Shigella* species (Fig. S3F) [27]. Surprisingly, infection with O-Ag
178 deficient ($\Delta O\text{-Ag}$) *S. sonnei*, and not T3SS deficient ($\Delta mxid$) *S. sonnei*, recapitulates results
179 obtained with *S. sonnei* -pSS (Fig. 3A-D). Consistent with a role for O-Ag in *S. sonnei*
180 virulence, dual-RNAseq profiling identified *wzzB/SSON53G_RS12230* (a protein involved in
181 the extension of O-Ag oligosaccharide chains) as significantly upregulated ($\text{Log}_2(\text{FC}) = 1.31$,
182 $\text{padj} = 3.31 \cdot 10^{-25}$) during zebrafish infection (Fig. S3G).

183

184 ***S. sonnei* O-antigen can counteract clearance by zebrafish neutrophils**

185 Considering that injection of *S. sonnei* induces recruitment of both macrophages and
186 neutrophils to the HBV at 6 hpi (Fig. 4A,B), we tested the role of these immune cells in *S.*
187 *sonnei* virulence. We used the zebrafish line *Tg(mpeg1:Gal4-FF)^{gl25}/Tg(UAS-*
188 *E1b:nfsB.mCherry*)^{c264} in which treatment with the pro-drug Metronidazole (Mtz) results in
189 macrophage ablation (Fig. S4A-C). Here, the presence or absence of macrophages does not

190 significantly affect zebrafish survival or bacterial burden (**Fig. 4C,D, Fig. S4D,E**). In contrast,
191 when both macrophages and neutrophils are depleted using *pu.1* morpholino oligonucleotide,
192 we observe a significant increase in zebrafish susceptibility to *S. sonnei* and bacterial burden
193 (**Fig. 4E,F**).

194
195 Considering an important role for neutrophils in *Shigella* control [21,23], and the significant
196 upregulation of genes involved in granulopoiesis/neutrophil chemotaxis identified by dual-
197 RNAseq profiling (e.g., *cepbp*, *atf3*, *cxcl8a*, *cxcl18b* (**Fig. 1C,D, Fig. 2E**)), we reasoned that
198 Δ O-Ag *S. sonnei* may be attenuated *in vivo* because of its inability to counteract neutrophil
199 clearance. Consistent with this hypothesis, infection of *pu.1* morphants at 30 hpf (when
200 depletion of immune cells is complete) with Δ O-Ag *S. sonnei* led to significantly increased
201 zebrafish death and bacterial burden, compared to control morphants at the same
202 developmental stage (**Fig. 4G,H, Fig. S4F-G**).

203
204 **S. sonnei can resist phagolysosome acidification and promote neutrophil cell death in**
205 **an O-antigen-dependent manner**

206 Using high resolution confocal microscopy, we observed that *S. sonnei* mostly reside within
207 neutrophil phagosomes at 3 hpi (**Fig. 5A**). Additionally, staining of live bacteria with a pH
208 sensitive dye (pHrodo) showed that intracellular *S. sonnei* mostly reside within acidic
209 compartments (**Fig. 5B**). We therefore hypothesised that O-Ag may promote bacterial survival
210 during phagolysosome acidification. To test this, we measured the growth of WT or Δ O-Ag *S.*
211 *sonnei* grown in liquid culture at different pH. While the growth of both strains is similar at
212 neutral pH = 7, WT *S. sonnei* grew significantly faster than Δ O-Ag *S. sonnei* at pH = 5 (**Fig.**
213 **5C,D, Fig. S5A,B**). Consistent with a role for O-Ag in tolerance to phagolysosome
214 acidification, transmission electron microscopy (TEM) of zebrafish larvae at 3 hpi showed
215 intact and dividing WT *S. sonnei* cells, versus disrupted and non-dividing Δ O-Ag *S. sonnei*
216 cells, in neutrophil phagosomes (**Fig. 5E,F, Fig. S5C**). Moreover, only in the case of WT *S.*

217 *sonnei* could we observe compromised nuclei and extranuclear chromatin in zebrafish cells
218 harbouring infection, indicative of necrotic cell death (**Fig. S5D**).

219
220 To investigate whether neutrophil cell death mediated by *S. sonnei* is dependent on O-Ag, we
221 quantified neutrophils at the whole animal level in WT or Δ O-Ag *S. sonnei* infected larvae at 6
222 and 24 hpi. Infection with WT *S. sonnei* resulted in significantly more neutrophil cell death than
223 infection with Δ O-Ag *S. sonnei* (**Fig. 5G-J**). In the case of *S. flexneri* infection, neutrophils are
224 recognised to die via necrosis [28]. Since no pharmacological reagent exists to directly test
225 necrosis *in vivo*, we sought to rule out other cell death pathways in *S. sonnei* infected larvae
226 and inhibited apoptosis, pyroptosis and/or necroptosis using the pan-caspase inhibitor Q-VD-
227 OPh (an inhibitor of apoptosis and pyroptosis), Necrostatin-1 and/or Necrostatin-5 (inhibitors
228 of necroptosis) (**Fig. S5E**). All inhibitors tested fail to significantly increase zebrafish survival.
229 Considering this, and that infected zebrafish cells appeared necrotic by TEM (**Fig. S5D**), we
230 conclude that neutrophils infected with *S. sonnei* undergo necrosis (and not a programmed
231 mechanism of cell death) because of bacterial survival enabled by *S. sonnei* O-Ag.

232
233 **Phagolysosome acidification controls *S. sonnei* clearance by zebrafish and human**
234 **neutrophils**

235 To test the role of phagolysosome acidification during *S. sonnei* infection *in vivo*, we treated
236 infected larvae with baflomycin, an inhibitor of vacuolar H⁺ ATPase (V-ATPase). Consistent
237 with a role for phagolysosome acidification in *S. sonnei* control, baflomycin treatment
238 significantly increased zebrafish susceptibility to *S. sonnei* (**Fig. 6A**). Baflomycin treatment
239 also increased zebrafish susceptibility to Δ O-Ag *S. sonnei* (**Fig. 6B**), highlighting the virulence
240 of Δ O-Ag *S. sonnei* in the absence of phagolysosome acidification.

241
242 Considering that inhibition of phagolysosome acidification increases zebrafish susceptibility to
243 *S. sonnei*, we hypothesised that promotion of acidification may overcome tolerance provided
244 by O-Ag *in vivo*. V-ATPases mediate phagolysosome acidification by using ATP to pump

245 protons in acidifying compartments. Injections of 200 μ M ATP 3 h prior to *S. sonnei* infection
246 significantly increases zebrafish survival (**Fig. 6C**). Bafilomycin directly antagonises V-
247 ATPase activity. In agreement with this, treatment of *S. sonnei* infected larvae with bafilomycin
248 counteracts the beneficial effects of ATP injection for host defence (**Fig. 6D**).

249

250 To test the role of *S. sonnei* O-Ag in human infection, we isolated peripheral neutrophils from
251 healthy donors and infected them with WT or Δ O-Ag *S. sonnei* (**Fig. 6E**). In agreement with
252 results from zebrafish infection, Δ O-Ag *S. sonnei* are significantly more susceptible to human
253 neutrophil-mediated clearance than WT bacteria and bafilomycin treatment increased
254 susceptibility of human neutrophils to Δ O-Ag *S. sonnei* (**Fig. 6F**). Plasmid reintroduction of the
255 O-Ag biosynthesis system in Δ O-Ag *S. sonnei* (Δ O-Ag $^{+pSSO-Ag}$) could restore the resistance of
256 mutant bacteria to neutrophil killing to levels observed using WT bacteria (**Fig. 6E-F**).
257 Collectively, these results show that *S. sonnei* O-Ag enables neutrophil tolerance in zebrafish
258 and human neutrophils, and suggest that promotion of phagolysosome acidification is a novel
259 approach to counteract *S. sonnei* infection.

260

261 **The innate immune system can be trained to control *S. sonnei* *in vivo***

262 Neutrophils of zebrafish larvae can be trained to protect against *S. flexneri* infection [24]. To
263 test if we can enhance innate immunity to *S. sonnei*, we developed a *S. sonnei* reinfection
264 assay (**Fig. 7A**). For this, larvae at 2 dpf were injected in the HBV with PBS or a sublethal
265 dose (~80 CFU) of WT or Δ O-Ag GFP-*S. sonnei*. At 48 hpi, we screened larvae and found
266 that ~20% of WT *S. sonnei* infected larvae are unable to clear infection (**Fig. S6A**); these
267 larvae were therefore excluded from further analysis. Next, PBS-injected larvae or larvae
268 clearing the primary infection (as determined by fluorescence microscopy) were infected with
269 a lethal dose (~8000 CFU) of mCherry-*S. sonnei*. Strikingly, injection of larvae with WT *S.*
270 *sonnei* (but not Δ O-Ag *S. sonnei*) significantly increased survival, as compared to PBS-
271 injected larvae (**Fig. 7B-C**). These experiments show that larvae exposed to a sublethal dose

272 of *S. sonnei* are protected against a secondary lethal dose of *S. sonnei* in an O-Ag-dependent
273 manner, and may have important implications in vaccine design.

274

275

276 **Discussion**

277 Why *S. sonnei* is emerging globally as a primary agent of bacillary dysentery has been
278 unknown. Here, we discover that *S. sonnei* is more virulent than *S. flexneri* *in vivo* because of
279 neutrophil tolerance mediated by its O-Ag. We also show that increased phagolysosomal
280 acidification or innate immune training can promote *S. sonnei* clearance by neutrophils *in vivo*
281 and propose new approaches to *S. sonnei* control.

282

283 The O-Ag, a lipopolysaccharide component of Gram-negative bacteria consisting of repetitive
284 surface oligosaccharide units, is a major target for the immune system and bacteriophages.
285 As a result, it is viewed that co-evolution of bacteria with their hosts or phages has led to
286 significant variation in O-Ag structure/composition across bacterial strains [29]. In the case of
287 most *Shigella* spp, significant variation of their *E. coli*-like O-Ag is observed across strains
288 [27]. Interestingly, genes involved in *S. sonnei* O-Ag biosynthesis are non-homologous to
289 those of other *Shigella* spp, highly conserved across *S. sonnei* strains and the only example
290 of a virulence-plasmid encoded O-Ag system (in other *Shigella* spp the O-Ag is encoded by
291 chromosomal genes) [27]. Consistent with this, acquisition of O-Ag genes from *P. shigelloides*
292 is considered a defining event for the emergence of *S. sonnei* [15,30]. We show that *S. sonnei*
293 O-Ag enables bacteria to resist phagolysosome acidification and promotes neutrophil cell
294 death. In agreement with this, chemical inhibition or promotion of phagolysosome acidification
295 respectively decreases and increases neutrophil control of *S. sonnei* and zebrafish survival.
296 In future studies it will be important to investigate the precise role of *S. sonnei* O-Ag in
297 tolerance to phagolysosome acidification in neutrophils, and inspire new approaches for *S.*
298 *sonnei* control.

299

300 Innate immune memory is a primitive form of immune memory conserved across vertebrates
301 [31,32]. We reveal that larvae injected with a sublethal dose of *S. sonnei* are protected against
302 a secondary lethal dose of *S. sonnei* in an O-Ag-dependent manner. Although there is no
303 vaccine currently available for *S. sonnei*, our results suggest that training innate immune
304 memory against O-Ag should be considered for vaccine development. Moreover, it is tempting
305 to speculate that innate immune memory may help to explain the increasing *S. sonnei* burden
306 in regions where improved water sanitisation has eliminated *P. shigelloides* and subsequently
307 reduced cross-immunisation against *S. sonnei* O-Ag [15,16]. Consistent with this, the
308 incidence of *S. sonnei* infection is mostly observed in very young children (<5 years old) [33–
309 37], an age group where trained innate immunity has been shown to play an important
310 protective role [31,32,38–40].

311

312 Collectively, these findings reveal O-antigen as an important therapeutic target against
313 bacillary dysentery. These findings also have major implications for our evolutionary
314 understanding of *Shigella* and may explain the increasing burden of *S. sonnei* in developing
315 countries.

316

317

318 **Materials and Methods**

319 **Ethics statements**

320 Animal experiments were performed according to the Animals (Scientific Procedures) Act
321 1986 and approved by the Home Office (Project licenses: PPL P84A89400 and P4E664E3C).
322 All experiments were conducted up to 7 days post fertilisation.

323

324 Tissue samples from anonymised human donors (neutrophils) were provided by the Imperial
325 College Healthcare NHS Trust Tissue Bank 12275. Other investigators may have received
326 samples from these same tissues.

327

328 **Zebrafish**

329 Zebrafish lines used here were the wildtype (WT) AB strain, macrophage reporter line
330 *Tg(mpeg1:Gal4-FF)^{gl25}*/*Tg(UAS-E1b:nfsB.mCherry)^{c264}* and neutrophil reporter line
331 *Tg(lyz:dsRed)^{nz50}*. Unless specified otherwise, eggs, embryos and larvae were reared at
332 28.5°C in Petri dishes containing embryo medium, consisting of 0.5x E2 water supplemented
333 with 0.3 µg/ml methylene blue (Sigma-Aldrich, St. Louis, Missouri). For injections and *in vivo*
334 imaging, anaesthesia was obtained with buffered 200 µg/ml tricaine (Sigma-Aldrich) in embryo
335 medium. Protocols are in compliance with standard procedures as reported at zfin.org.

336

337 **Bacterial preparation and infection delivery**

338 Unless specified otherwise, GFP fluorescent or non-fluorescent *S. flexneri* M90T or *S. sonnei*
339 53G were used. Mutant, transgenic and WT strains are as indicated in the Figure legends and
340 further detailed in **Table S3**.

341

342 Bacteria were grown on trypticase soy agar (TSA, Sigma-Aldrich) plates containing 0.01%
343 Congo red (Sigma-Aldrich) supplemented, when appropriate, with antibiotics (Carbenicillin
344 100 µg/ml (Sigma-Aldrich), Kanamycin 50 µg/ml (Sigma-Aldrich), Streptomycin 50 µg/ml
345 (Sigma-Aldrich)). Individual colonies were selected and grown O/N, 37°C/200 rpm, in 5 ml
346 trypticase soy broth (TSB, Sigma-Aldrich) supplemented with the appropriate antibiotics as
347 above. For injections, bacteria were grown to Log phase by diluting 400 µl of O/N culture in
348 20 ml of fresh TSB (supplemented, where appropriate, with 25 µg/ml Carbenicillin) and
349 culturing as above until an optical density (OD) of 0.55-0.65 at 600 nm.

350

351 Bacteria were spun down, washed in phosphate buffer saline (PBS, Sigma-Aldrich) and
352 resuspended at the desired concentration in a final injection buffer containing 2%
353 polyvinylpyrrolidone (Sigma-Aldrich) and 0.5% phenol red (Sigma-Aldrich) in PBS (injection
354 buffer alone is referred into the text as PBS group).

355

356 Unless specified otherwise, 1-2 nl of bacterial suspension (bacterial load as indicated in the
357 individual experiments) or control solution were microinjected in the hindbrain ventricle (HBV)
358 of 3 days post-fertilisation (dpf) zebrafish larvae (or at 2 dpf followed by reinfection at 4 dpf for
359 reinfection assays, **Fig. 7B,C**). In **Fig. S1G,H** infection was delivered intravenously (IV), via
360 the Duct of Cuvier.

361

362 Bacterial enumeration was performed *a posteriori* by mechanical disruption of infected larvae
363 in 0.4% Triton X-100 (Sigma-Aldrich) and plating of serial dilutions onto Congo red-TSA plates.
364 The *S. sonnei* 53G $\Delta tssB$ strain was created using the λ Red recombinase approach [41].
365 Briefly, a Kan^R construct with flanking extensions homologous to the upstream and
366 downstream regions of *tssB* was created by overlapping PCR using primers #1 and #2
367 (upstream *tssB*), #3 and #4 (downstream *tssB*) and #5 and #6 (Kan^R). Primer sequences are
368 reported in **Table S4**. The linear fragment was amplified (primers #1 and #4), parental plasmid
369 removed by DpnI digestion and the linear fragment gel purified. The linear fragment was
370 transformed into electrocompetent *S. sonnei* 53G containing pKD46; the λ Red recombinase
371 genes on this plasmid were induced by arabinose prior to transformation. $\Delta tssB$ colonies were
372 selected on Kanamycin plates, and gene disruption was verified by multiple PCRs (primers #7
373 and #8, #7 and #9). pKD46 loss was confirmed by Ampicillin sensitivity. Successful gene
374 disruption was also confirmed by sequencing of the entire region using primers #9 and #10.

375

376 To quantify the loss of virulence plasmid (**Fig. S3E**) GFP-labeled bacteria were injected in
377 zebrafish larvae (1nl, ~7000 CFU/nl) as above or spotted onto Congo red-TSA plates (10 μ l,

378 ~7000 CFU/ml). Larvae and plates were incubated at 28.5°C for 24 h, bacteria were harvested
379 from plates or larvae, and plated in serial dilutions on Carbenicillin-supplemented plates,
380 grown O/N at 37°C and quantified for loss of virulence plasmid (white versus red colonies) as
381 described elsewhere [26].

382

383 To address sensitivity of bacterial strains to acidic pH (**Fig. 5C,D, Fig. S5A,B**), bacteria were
384 first grown O/N as described above, diluted to the same initial OD₆₀₀ (0.10) in pH-adjusted
385 TSB and bacterial growth was monitored by OD₆₀₀ measurements at different timepoints. The
386 pH of TSB was adjusted by addition of few drops of concentrated HCl (Sigma-Aldrich).

387

388 **Infection of human neutrophils**

389 At least 5 ml of peripheral blood was drawn from healthy volunteers, using EDTA as an
390 anticoagulant (BD Vacutainer, Becton Dickinson, Franklin Lakes, New Jersey). Neutrophils
391 were isolated by gradient centrifugation using Polymorphprep™ (Axis-Shield, Dundee, UK),
392 according to the manufacturer's guidelines and previously described protocols [42]. Residual
393 erythrocytes were removed by incubation for 10 minutes at 37°C in erythrocyte lysis buffer,
394 consisting of 0.83% w/v NH₄Cl (Sigma-Aldrich), 10 mM NaOH-buffered HEPES (4-(2-
395 hydroxyethyl)-1-piperazineethanesulfonic acid, Sigma-Aldrich), pH 7.4. Purified neutrophils
396 were washed in Hank's Balanced Salt Solution (HBSS) without Calcium and Magnesium
397 (HBSS -Ca²⁺/Mg²⁺, ThermoFisher Scientific, Waltham, Massachusetts), resuspended in
398 neutrophil medium, consisting of HBSS with Calcium and Magnesium (HBSS +Ca²⁺/+Mg²⁺,
399 ThermoFisher Scientific) and 0.1% porcine gelatin (Sigma-Aldrich), counted using trypan blue
400 staining, and ultimately diluted at a density of 2 x 10⁶ live cells/ml in neutrophil medium [42].
401 Prior receiving infection, 10⁵ neutrophils (50 µl of neutrophil resuspension) were pre-incubated
402 with Bafilomycin (111,11 nM, Sigma-Aldrich) [43,44] or DMSO at vehicle control levels for 30
403 minutes with gentle shaking at 37°C in 48-well plates and in a total volume of 180 µl of
404 neutrophil medium.

405

406 For neutrophil infections, *Shigella* was cultured as described above, but ultimately
407 resuspended in neutrophil medium at a density of 5×10^4 CFU/ml and 10^3 bacteria (20 μ l of
408 bacterial resuspension) were added to the neutrophil resuspension and incubated for 1 h with
409 gentle shaking at 37°C. Neutrophils were lysed by incubation on ice and addition of 7.5 μ l of
410 0.4% Triton X-100 (Sigma-Aldrich) per well. Total CFUs were calculated by plating 20 μ l of
411 the lysate, comparing infected neutrophil samples to control samples, lacking neutrophils [42].

412

413 **pHrodo staining**

414 pHrodo™ Red, succinimidyl ester (Thermofisher scientific) was prepared according to the
415 manufacturer's guidelines. 0.25 μ l of stock solution were used to stain 200 μ l of a ~7000
416 CFU/ml bacterial suspension in PBS. Bacteria were incubated in the dark at 28.5°C for 30
417 minutes, washed 3 times in PBS, resuspended in 2% polyvinylpyrrolidone and 0.5% phenol
418 red in PBS and injected in the HBV as above.

419

420 **Light and electron microscopy imaging**

421 Stereo fluorescent microscopy images were acquired using Leica M205FA stereo fluorescent
422 microscopes (Leica, Wetzlar, Germany). Zebrafish larvae were anaesthetised and aligned on
423 1% agarose plates in embryo medium.

424

425 For high-resolution confocal microscopy, imaging was performed using a Zeiss LSM 880 (Carl
426 Zeiss, Oberkochen, Germany). Larvae were positioned in 35-mm-diameter glass-bottom
427 MatTek dishes and imaged with 20× air or 40× water immersion objectives. Image files were
428 processed using ImageJ/FIJI software.

429

430 For electron microscopy analysis, infected zebrafish larvae and controls were fixed at 3 hpi
431 in 0.5% glutaraldehyde/200 nM sodium cacodylate buffer for 2 h and washed in cacodylate
432 buffer only. Samples were then fixed in reduced 1% osmium tetroxide/1.5% potassium

433 ferricyanide for 60 min, washed in distilled water and stained overnight at 4°C in 0.5%
434 magnesium uranyl acetate. Specimens were then washed in distilled water, dehydrated in
435 graded ethanol, infiltrated with propylene oxide and then graded Epon/PO mixtures until
436 final embedding in full Epon resin in coffin moulds. Resin was allowed to polymerise at 56°C
437 overnight, then semi-thin survey sections were cut and stained. Final ultrathin sections
438 (typically 50–70 nm) and serial sections were collected on Formvar coated slot grids,
439 stained with Reynold's lead citrate and examined in a FEI Tecnai electron microscope with
440 CCD camera image acquisition system.

441

442 **qRT-PCR**

443 qRT-PCRs were performed using StepOne Plus machine (Applied Biosystems, Foster City,
444 California) and a SYBR green master mix (Applied Biosystems). Briefly, RNA was isolated
445 from pools of whole larvae using RNeasy mini kit (Qiagen, Hilden, Germany). cDNA was
446 obtained using a QuantiTect reverse transcription kit (Qiagen). Samples were run in technical
447 duplicates and quantification was obtained using the $2^{-\Delta\Delta CT}$ method and *eef1a1a* as a
448 housekeeping gene. **Table S4** reports all primers used in this study.

449

450 **Enumeration of immune cells**

451 For recruitment assays, immune cells attracted to the infection site were enumerated from
452 images by counting *Tg(mpeg1:Gal4-FF)^{gl25}/Tg(UAS-E1b:nfsB.mCherry)^{c264}* (for
453 macrophages) or *Tg(lyz:dsRed)^{nz50}* (for neutrophils) positive cells in the hindbrain/midbrain.
454 To quantify neutrophil death, the same neutrophil line was used to count immune cells at the
455 whole animal level.

456

457 **Chemical treatments, ablations and knockdowns in zebrafish**

458 Macrophages were ablated by exposing hatched 2 dpf *Tg(mpeg1:Gal4-FF)^{gl25}/Tg(UAS-*
459 *E1b:nfsB.mCherry)^{c264}* embryos to Metronidazole (Mtz, Sigma-Aldrich) at 100 μ M

460 concentration in 1% DMSO (Sigma-Aldrich) for 24 h [45]. Treatment with 1% DMSO alone
461 was used as a control.

462

463 Morpholinos were purchased from Gene Tools (Philomath, Oregon). Injections of *pu.1*
464 (*spi1ab*) morpholino (2 nl, 0.5 mM in 0.5% phenol red) were performed at 1-cell stage and the
465 same volume and concentration of a standard control morpholino was used as negative
466 control. Morpholino sequences are reported in **Table S4**.

467

468 Necrostatin-1 (10 μ M, Santa Cruz Biotechnology, Dallas, Texas), Necrostatin-5 (10 μ M, Santa
469 Cruz) [46], Q-VD-OPh (50 μ M, Sigma-Aldrich) [47] and Bafilomycin (200 nM, Sigma-Aldrich)
470 [43,48] were provided by bath exposure from 0 hpi for the whole infection course. Exposure
471 to DMSO at vehicle concentration (0.67% for Necrostatin-1, Necrostatin-5, Q-VD-OPh, and
472 0.2% for Bafilomycin) was used as a control. Priming with ATP injections was performed by
473 injecting 1 nl of 200 mM ATP in the hindbrain 3 h prior infection. Injection of 1 nl of sterile water
474 was used as a vehicle control.

475

476 **Dual-RNAseq sample preparation and analysis**

477 RNA samples for dual-RNAseq were extracted in triplicate from infected larvae at 24 hpi using
478 24 larvae/sample. As a control for the host transcriptome, RNA was isolated from
479 corresponding PBS injected larvae at the same timepoint. As a control for *S. sonnei*
480 transcriptome, RNA was isolated from the same culture used for injection, but diluted 50x and
481 subcultured at 28.5°C until it reached the OD of ~0.6 in a total volume of 5 ml. Samples were
482 snap frozen at -80°C, then 100 μ l of RNA protect bacteria reagent (Qiagen) was added,
483 followed by mechanical trituration with a pestle blender. Samples were supplemented with
484 100 μ l of 30 mM Tris-HCl/1 mM EDTA solution at pH = 8, 33 μ l of 50 mg/ml lysozyme (Thermo
485 Scientific), 33 μ l of proteinase K >600 U/ml (Thermo Scientific) and shaken for 20 min RT.
486 Lysis was completed by adding 700 μ l of RTL buffer (Qiagen), 3 μ l of 1 M dithiothreitol (Sigma-

487 Aldrich) and mechanical disruption. Undigested debris were spun down 3 min 10000 rpm and
488 the supernatant was supplemented with 500 μ l of 100% ethanol prior loading onto RNeasy
489 mini columns (Qiagen). From this step onwards, the manufacturer's guidelines were followed
490 for RNA purification. RNA quality and integrity were assessed by using NanoDrop and Non-
491 denaturing agarose gel electrophoresis. For further quality check, RNA sequencing, library
492 construction and reads count, samples were outsourced to Vertis Biotechnologie AG (Freising,
493 Germany). Bacterial and host mRNA were enriched prior library preparation by using Ribo-
494 Zero Gold rRNA Removal Kit (Epidemiology, Illumina, San Diego, California). The zebrafish
495 genome assembly GRCz11 (<http://www.ensembl.org/Danio rerio>) and the *S. sonnei* 53G
496 genome assembly ASM28371v1 (<https://www.ncbi.nlm.nih.gov/assembly/406998>) were used
497 to guide mapping of host and pathogen reads, respectively. The average library depths for the
498 different sample groups were: 8658688 +/- 598491 reads (PBS injected larvae), 7771779 +/-
499 804881 reads (infected larvae), 11315345 +/- 551602 reads (*S. sonnei* *in vitro*) and 702385 +/-
500 12785 reads (*S. sonnei* *in vivo*).

501
502 RNAseq statistical analysis was performed using DESeq2 package in R [49,50]. Genes that
503 were not represented with at least 6 reads cumulative from all samples were excluded from
504 the analysis *a priori*. Genes were accepted as differentially expressed if the DESeq2 $\text{Log}_2(\text{Fold}$
505 $\text{Change}) > |1|$ and DESeq2 adjusted p value (padj) < 0.05 . Heatmaps (**Fig. 2D,E**) were
506 obtained from counts per million (CPM) reads using the "pheatmap" package (<https://CRAN.R->
507 [project.org/package=pheatmap](https://CRAN.R-project.org/package=pheatmap)). Principal component analysis (PCA) (**Fig. S2A,B**) was also
508 performed in R from CPM reads, using the dedicated PCA tools [50]. All the other graphs were
509 generated using GraphPad Prism 7 (GraphPad Software, San Diego, California). Host
510 pathway enrichment analysis and enrichment of transcription factor binding sites were
511 performed using ShinyGO v0.60 (<http://bioinformatics.sdsu.edu/go/>) [51]. Due to poor
512 annotations of *S. sonnei* Gene Ontology functions, pathogen pathway enrichment analysis
513 was performed manually on the top 50 differentially expressed genes, inferring protein funtions

514 from *E. coli* homologues of *S. sonnei* genes. Homologues were identified by direct protein
515 BLAST using the protein database available via uniprot.org.

516

517 **Statistical analysis and data processing**

518 Except for graphs performed in R, all other graphs and statistical analyses were performed
519 using GraphPad Prism 7. Statistical difference for survival curves were analysed using a Log-
520 rank (Mantel-Cox) test. Differences in CFU recovery and gene expression levels were
521 quantified on Log₁₀-transformed or Log₂-transformed data, respectively. To avoid Log(0), i.e.,
522 when no colonies were recovered, the CFU counts were assigned as 1. When only 2 groups
523 were compared, significant differences were tested using an unpaired t-test at each timepoint.
524 When more than 2 groups were compared, a one-way ANOVA with Sidak's correction was
525 used. Unpaired t-test (comparison between 2 groups) or one-way ANOVA with Sidak's
526 correction (comparison between more than 2 groups) was also applied to **Fig. S3E, Fig. 5C,D,**
527 **Fig. S5A,B** and **Fig. 6. E,F** but on non-transformed data, as in this case a parametric
528 distribution could be assumed. Statistics for categorical data were obtained by a two-sided
529 chi-squared contingency test (**Fig. S1D, Fig. S6A**). For statistical quantification of immune cell
530 numbers (non-parametric data), a two-tailed Mann-Whitney test (comparison between 2
531 groups) or a Kruskal-Wallis test with Dunn's correction (comparison between more than 2
532 groups) was used.

533

534

535 **Acknowledgements**

536 We thank Margarida C. Gomes and Nagisa Yoshida for helpful discussion.

537

538

539 **Competing Interests**

540 The authors declare no competing financial or non-financial interests that might have
541 influenced the work described in this manuscript.

542

543

544 **References**

- 545 1. Khalil IA, Troeger C, Blacker BF, Rao PC, Brown A, Atherly DE, et al. Morbidity and
546 mortality due to *Shigella* and enterotoxigenic *Escherichia coli* diarrhoea: the global
547 burden of disease study 1990-2016. *Lancet Infect Dis.* 2018;18: 1229–1240.
548 doi:10.1016/S1473-3099(18)30475-4
- 549 2. Kotloff KL, Riddle MS, Platts-Mills JA, Pavlinac P, Zaidi AKM. Shigellosis. *Lancet.*
550 2018;391: 801–812. doi:10.1016/S0140-6736(17)33296-8
- 551 3. World Health Organization. Global priority list of antibiotic-resistant bacteria to guide
552 research, discovery, and development of new antibiotics. WHO Press. WHO Press;
553 2017
- 554 4. Baker KS, Dallman TJ, Field N, Childs T, Mitchell H, Day M, et al. Horizontal
555 antimicrobial resistance transfer drives epidemics of multiple *Shigella* species. *Nat
556 Commun.* 2018;9: 1462. doi:10.1038/s41467-018-03949-8
- 557 5. Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, Weiss DS, et al.
558 Neutrophil extracellular traps kill bacteria. *Science.* 2004;303: 1532–1435.
559 doi:10.1126/science.1092385
- 560 6. Girardin SE, Boneca IG, Carneiro LAM, Antignac A, Jéhanno M, Viala J, et al. Nod1
561 detects a unique muropeptide from Gram-negative bacterial peptidoglycan. *Science.*
562 2003;300: 1584–1587. doi:10.1126/science.1084677
- 563 7. Ogawa M, Yoshimori T, Suzuki T, Sagara H, Mizushima N, Sasakawa C. Escape of
564 intracellular *Shigella* from autophagy. *Science.* 2005;307: 727–731.
565 doi:10.1126/science.1106036
- 566 8. Li P, Jiang W, Yu Q, Liu W, Zhou P, Li J, et al. Ubiquitination and degradation of GBPs

- 567 by a *Shigella* effector to suppress host defence. *Nature*. 2017;551: 378–383.
568 doi:10.1038/nature24467
- 569 9. Wandel MP, Pathe C, Werner EI, Ellison CJ, Boyle KB, von der Malsburg A, et al. GBPs
570 inhibit motility of *Shigella flexneri* but are targeted for degradation by the bacterial
571 ubiquitin ligase IpaH9.8. *Cell Host Microbe*. 2017;22: 507-518.e5.
572 doi:10.1016/j.chom.2017.09.007
- 573 10. Krokowski S, Lobato-Márquez D, Chastanet A, Pereira PM, Angelis D, Galea D, et al.
574 Septins recognize and entrap dividing bacterial cells for delivery to lysosomes. *Cell Host
575 Microbe*. Elsevier; 2018;24: 866-874.e4. doi:10.1016/j.chom.2018.11.005
- 576 11. Mostowy S, Bonazzi M, Hamon MA, Tham TN, Mallet A, Lelek M, et al. Entrapment of
577 intracytosolic bacteria by septin cage-like structures. *Cell Host Microbe*. 2010;8: 433–
578 444. doi:10.1016/j.chom.2010.10.009
- 579 12. Pupo GM, Lan R, Reeves PR. Multiple independent origins of *Shigella* clones of
580 *Escherichia coli* and convergent evolution of many of their characteristics. *Proc Natl
581 Acad Sci*. 2000;97: 10567–10572. doi:10.1073/pnas.180094797
- 582 13. Holt KE, Baker S, Weill F-X, Holmes EC, Kitchen A, Yu J, et al. *Shigella sonnei* genome
583 sequencing and phylogenetic analysis indicate recent global dissemination from
584 Europe. *Nat Genet*. 2012;44: 1056–1059. doi:10.1038/ng.2369
- 585 14. Kotloff KL, Winickoff JP, Ivanoff B, Clemens JD, Swerdlow DL, Sansonetti PJ, et al.
586 Global burden of *Shigella* infections: implications for vaccine development and
587 implementation of control strategies. *Bull World Health Organ*. 1999;77: 651–666.
- 588 15. Thompson CN, Duy PT, Baker S. The rising dominance of *Shigella sonnei*: an
589 intercontinental shift in the etiology of bacillary dysentery. *PLoS Negl Trop Dis*. 2015;9:
590 e0003708. doi:10.1371/journal.pntd.0003708
- 591 16. Sack DA, Hoque AT, Huq A, Etheridge M. Is protection against shigellosis induced by
592 natural infection with *Plesiomonas shigelloides*? *Lancet*. 1994;343: 1413–1415.
593 doi:10.1016/S0140-6736(94)92531-3
- 594 17. Anderson MC, Vonaesch P, Saffarian A, Marteyn BS, Sansonetti PJ. *Shigella sonnei*

- 595 encodes a functional T6SS used for interbacterial competition and niche occupancy.
- 596 *Cell Host Microbe.* 2017;21: 769-776.e3. doi:10.1016/j.chom.2017.05.004
- 597 18. Torraca V, Mostowy S. Zebrafish infection: from pathogenesis to cell biology. *Trends*
- 598 *Cell Biol.* 2018;28: 143–156. doi:10.1016/j.tcb.2017.10.002
- 599 19. Gomes MC, Mostowy S. The case for modelling human infection in zebrafish. *Trends*
- 600 *Microbiol.* 2019; *in press*
- 601 20. Duggan GM, Mostowy S. Use of zebrafish to study *Shigella* infection. *Dis Model Mech.*
- 602 2018;11: dmm032151. doi:10.1242/dmm.032151
- 603 21. Mostowy S, Boucontet L, Mazon Moya MJ, Sirianni A, Boudinot P, Hollinshead M, et
- 604 al. The zebrafish as a new model for the in vivo study of *Shigella flexneri* interaction
- 605 with phagocytes and bacterial autophagy. *PLoS Pathog.* 2013;9: e1003588.
- 606 doi:10.1371/journal.ppat.1003588
- 607 22. Willis AR, Moore C, Mazon-Moya M, Krokowski S, Lambert C, Till R, et al. Injections of
- 608 predatory bacteria work alongside host immune cells to treat *Shigella* infection in
- 609 zebrafish larvae. *Curr Biol.* 2016;26: 3343–3351. doi:10.1016/j.cub.2016.09.067
- 610 23. Mazon-Moya MJ, Willis AR, Torraca V, Boucontet L, Shenoy AR, Colucci-Guyon E, et
- 611 al. Septins restrict inflammation and protect zebrafish larvae from *Shigella* infection.
- 612 *PLoS Pathog.* 2017;13: e1006467. doi:10.1371/journal.ppat.1006467
- 613 24. Willis AR, Torraca V, Gomes MC, Shelley J, Mazon-Moya M, Filloux A, et al. *Shigella*-
- 614 induced emergency granulopoiesis protects zebrafish larvae from secondary infection.
- 615 *MBio.* 2018;9. doi:10.1128/mBio.00933-18
- 616 25. Caboni M, Pédrón T, Rossi O, Goulding D, Pickard D, Citiulo F, et al. An O-antigen
- 617 capsule modulates bacterial pathogenesis in *Shigella sonnei*. *PLoS Pathog.* 2015;11:
- 618 e1004749. doi:10.1371/journal.ppat.1004749
- 619 26. McVicker G, Tang CM. Deletion of toxin–antitoxin systems in the evolution of *Shigella*
- 620 *sonnei* as a host-adapted pathogen. *Nat Microbiol.* 2017;2: 16204.
- 621 doi:10.1038/nmicrobiol.2016.204
- 622 27. Liu B, Knirel YA, Feng L, Perepelov A V., Senchenkova SN, Wang Q, et al. Structure

- 623 and genetics of *Shigella* O-antigens. FEMS Microbiol Rev. 2008;32: 627–653.
624 doi:10.1111/j.1574-6976.2008.00114.x
- 625 28. François M, Le Cabec V, Dupont MA, Sansonetti PJ, Maridonneau-Parini I. Induction
626 of necrosis in human neutrophils by *Shigella flexneri* requires type III secretion, IpaB
627 and IpaC invasins, and actin polymerization. Infect Immun. 2000;68: 1289–1296.
628 doi:10.1128/IAI.68.3.1289-1296.2000
- 629 29. Wang L, Wang Q, Reeves PR. The variation of O-antigens in Gram-negative bacteria.
630 Subcell Biochem. 2010;53: 123–152. doi:10.1007/978-90-481-9078-2_6
- 631 30. Shepherd JG, Wang L, Reeves PR. Comparison of O-antigen gene clusters of
632 *Escherichia coli* (*Shigella*) *sonnei* and *Plesiomonas shigelloides* O17: *sonnei* gained its
633 current plasmid-borne O-antigen genes from *P. shigelloides* in a recent event. Infect
634 Immun. 2000;68: 6056–6061. doi:10.1128/IAI.68.10.6056-6061.2000
- 635 31. Arts RJW, Moorlag SJCFM, Novakovic B, Li Y, Wang SY, Oosting M, et al. BCG
636 vaccination protects against experimental viral Infection in humans through the
637 induction of cytokines associated with trained immunity. Cell Host Microbe. 2018;23:
638 89-100.e5. doi:10.1016/j.chom.2017.12.010
- 639 32. Netea MG, Joosten LAB, Latz E, Mills KHG, Natoli G, Stunnenberg HG, et al. Trained
640 immunity: a program of innate immune memory in health and disease. Science.
641 2016;352: aaf1098–aaf1098. doi:10.1126/science.aaf1098
- 642 33. Ashkenazi S, May-Zahav M, Dinari G, Gabbay U, Zilberberg R, Samra Z. Recent trends
643 in the epidemiology of *Shigella* species in Israel. Clin Infect Dis. 1993;17: 897–899.
644 doi:10.1093/clinids/17.5.897
- 645 34. Ashkenazi S. *Shigella* infections in children: New insights. Semin Pediatr Infect Dis.
646 2004;15: 246–252. doi:10.1053/j.spid.2004.07.005
- 647 35. Ranjbar R, Soltan Dallal MM, Talebi M, Pourshafie MR. Increased isolation and
648 characterization of *Shigella sonnei* obtained from hospitalized children in Tehran, Iran.
649 J Health Popul Nutr. 2008;26: 426–430. doi:10.3329/jhpn.v26i4.1884
- 650 36. Simon AK, Hollander GA, McMichael A. Evolution of the immune system in humans

- 651 from infancy to old age. *Proc R Soc B Biol Sci.* 2015;282: 20143085.
652 doi:10.1098/rspb.2014.3085
- 653 37. Zhao L, Xiong Y, Meng D, Guo J, Li Y, Liang L, et al. An 11-year study of shigellosis
654 and *Shigella* species in Taiyuan, China: active surveillance, epidemic characteristics,
655 and molecular serotyping. *J Infect Public Health.* 2017;10: 794–798.
656 doi:10.1016/j.jiph.2017.01.009
- 657 38. Arts RJW, Joosten LAB, Netea MG. The potential role of trained immunity in
658 autoimmune and autoinflammatory disorders. *Front Immunol.* 2018;9: 298.
659 doi:10.3389/fimmu.2018.00298
- 660 39. Butkeviciute E, Jones CE, Smith SG. Heterologous effects of infant BCG vaccination:
661 potential mechanisms of immunity. *Future Microbiol.* 2018;13: 1193–1208.
662 doi:10.2217/fmb-2018-0026
- 663 40. Novakovic B, Messina NL, Curtis N. The heterologous effects of bacillus Calmette-
664 Guérin (BCG) vaccine and trained innate immunity. *The Value of BCG and TNF in
665 Autoimmunity.* Elsevier; 2018. pp. 71–90. doi:10.1016/B978-0-12-814603-3.00006-9
- 666 41. Datsenko KA, Wanner BL. One-step inactivation of chromosomal genes in *Escherichia*
667 *coli* K-12 using PCR products. *Proc Natl Acad Sci.* 2000;97: 6640–6645.
668 doi:10.1073/pnas.120163297
- 669 42. Standish AJ, Weiser JN. Human neutrophils kill *Streptococcus pneumoniae* via serine
670 proteases. *J Immunol.* 2009;183: 2602–2609. doi:10.4049/jimmunol.0900688
- 671 43. Tapper H, Sundler R. Bafilomycin A1 inhibits lysosomal, phagosomal, and plasma
672 membrane H(+)-ATPase and induces lysosomal enzyme secretion in macrophages. *J
673 Cell Physiol.* John Wiley & Sons, Ltd; 1995;163: 137–144. doi:10.1002/jcp.1041630116
- 674 44. Prince LR, Bianchi SM, Vaughan KM, Bewley MA, Marriott HM, Walmsley SR, et al.
675 Subversion of a lysosomal pathway regulating neutrophil apoptosis by a major bacterial
676 toxin, pyocyanin. *J Immunol.* 2008;180: 3502–11. doi:10.4049/jimmunol.180.5.3502
- 677 45. Curado S, Stainier DYR, Anderson RM. Nitroreductase-mediated cell/tissue ablation in
678 zebrafish: a spatially and temporally controlled ablation method with applications in

- 679 developmental and regeneration studies. *Nat Protoc.* 2008;3: 948–954.
680 doi:10.1038/nprot.2008.58
- 681 46. Roca FJ, Ramakrishnan L. TNF dually mediates resistance and susceptibility to
682 mycobacteria via mitochondrial reactive oxygen species. *Cell. NIH Public Access;*
683 2013;153: 521–534. doi:10.1016/j.cell.2013.03.022
- 684 47. Tyrkalska SD, Candel S, Angosto D, Gómez-Abellán V, Martín-Sánchez F, García-
685 Moreno D, et al. Neutrophils mediate *Salmonella* Typhimurium clearance through the
686 GBP4 inflammasome-dependent production of prostaglandins. *Nat Commun.* 2016;7:
687 12077. doi:10.1038/ncomms12077
- 688 48. Levitte S, Adams KN, Berg RD, Cosma CL, Urdahl KB, Ramakrishnan L. Mycobacterial
689 acid tolerance enables phagolysosomal survival and establishment of tuberculous
690 infection *in vivo*. *Cell Host Microbe.* 2016;20: 250–258.
691 doi:10.1016/j.chom.2016.07.007
- 692 49. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for
693 RNA-seq data with DESeq2. *Genome Biol.* 2014;15: 550. doi:10.1186/s13059-014-
694 0550-8
- 695 50. RR Development Core Team. R: A language and environment for statistical computing.
696 2011.
- 697 51. Ge SX, Jung D. ShinyGO: a graphical enrichment tool for animals and plants. *bioRxiv.*
698 2018; doi:10.1101/315150
- 699 52. Castanié-Cornet MP, Cam K, Bastiat B, Cros A, Bordes P, Gutierrez C. Acid stress
700 response in *Escherichia coli*: Mechanism of regulation of GadA transcription by RcsB
701 and GadE. *Nucleic Acids Res.* 2010; doi:10.1093/nar/gkq097
- 702 53. Malki A, Le HT, Milles S, Kern R, Caldas T, Abdallah J, et al. Solubilization of protein
703 aggregates by the acid stress chaperones HdeA and HdeB. *J Biol Chem.* 2008;
704 doi:10.1074/jbc.M800869200
- 705 54. Foster JW, Richard H. *Escherichia coli* glutamate- and arginine-dependent acid
706 resistance systems increase internal pH and reverse transmembrane potential. *J*

707 Bacteriol. 2004; doi:PMC515135
708 55. Anderson M, Sansonetti PJ, Marteyn BS. *Shigella* diversity and changing landscape:
709 insights for the twenty-first century. Front Cell Infect Microbiol. 2016;6: 45.
710 doi:10.3389/fcimb.2016.00045

711

712

713 **Figure Legends**

714 **Figure 1. *S. sonnei* is more virulent than *S. flexneri* in a zebrafish infection model**

715 **A,B. *S. sonnei* is more virulent than *S. flexneri* in vivo.** Survival curves (A) and Log₁₀-
716 transformed CFU counts (B) of larvae injected in the hindbrain ventricle (HBV) with PBS (grey),
717 *S. flexneri* (blue) or *S. sonnei* (red). Experiments are cumulative of 3 biological replicates. In
718 B, full symbols represent live larvae and empty symbols represent larvae that at the plating
719 timepoint had died within the last 16 hours. Statistics: Log-rank (Mantel-Cox) test (A); unpaired
720 t-test on Log₁₀-transformed values (B); **p<0.0021; ***p<0.0002; ****p< 0.0001.

721 **C,D. *S. sonnei* elicits a stronger inflammatory signature than *S. flexneri* in vivo.**
722 Quantitative real time PCR for representative inflammatory markers were performed on pools
723 of 20 HBV injected larvae collected at 6 (C) or 24 (D) hpi with PBS (grey), *S. flexneri* (blue) or
724 *S. sonnei* (red). Experiments are cumulative of 4 biological replicates. Statistics: one-way
725 ANOVA with Sidak's correction on Log₂-transformed values; ns, non-significant; *p<0.0332
726 **p<0.0021; ***p<0.0002; ****p<0.0001.

727 **E,F. *S. sonnei* can disseminate from the injection site.** Representative images of three
728 GFP-labelled *S. flexneri*-infected (E) or *S. sonnei*-infected (F) larvae at 24 hpi. In D, arrows
729 indicate dissemination in the blood circulation; arrowheads indicate dissemination in the
730 neuronal tube. Scale bars = 1 mm.

731

732 **Figure 2. Whole animal dual-RNAseq profiling of *S. sonnei* infected larvae**

733 **A. Workflow for dual-RNAseq processing.** 3 dpf larvae were infected with ~7000 CFU of *S.*
734 *sonnei*. Pools of infected larvae were collected for RNA isolation at 24 hpi. As a control for the
735 bacterial transcriptome, the same cultures of *S. sonnei* were diluted 50x and subcultured at
736 28.5°C (same temperature at which infected larvae are maintained) until Log phase (OD_{600}
737 ~0.6) was reached. As a control for the zebrafish transcriptome, pools of PBS-injected larvae
738 at 24 hpi were used. Reads from infected larvae were mapped separately to both the *S. sonnei*
739 and zebrafish genomes, while reads from *S. sonnei* *in vitro* cultures and PBS injected larvae
740 were mapped to the pathogen or host genome, respectively.

741 **B,C. Volcano plots for bacterial and zebrafish genes during *S. sonnei* infection.** Each
742 datapoint refers to a single gene. Non significantly differentially expressed genes are shown
743 in grey, while significantly downregulated genes are shown in blue and significantly
744 upregulated genes are shown in red. Plot in B refers to *S. sonnei* genes and plot in C refers
745 to zebrafish genes. See also **Fig. S2** for additional details. $\text{Log}_2(\text{FC})$ and $-\text{Log}_{10}(\text{padj})$
746 coordinates were derived from data analysis with the DESeq2 package in R. In B, points
747 enclosed in the black rectangle were computed to have a DESeq2 padj = 0.

748 **D,E. Heatmap of the top 50 differentially expressed bacterial and zebrafish genes during**
749 ***S. sonnei* infection.** Columns represent individual biological replicates (R1, R2, R3).
750 Heatmaps were created from counts per million (CPM) reads values, using “pheatmap”
751 package in R. Shades of blue indicate downregulation and shades of red indicate upregulation
752 compared to baseline. Plot in D refers to *S. sonnei* genes and plot in E refers to zebrafish
753 genes. Gene names in brackets are inferred by manual annotations based on protein
754 alignments performed on the Uniprot database (<https://www.uniprot.org/>). For genes not
755 predicted to encode a protein, manual annotations were inferred from the Ensembl database
756 (<https://www.ensembl.org/>). (*) *si:dkey-183i3.5*: thread biopolymer filament subunit alpha-like;
757 *zgc:136930*: thread biopolymer filament subunit gamma-like; *si:ch211-153b23.4*: *YrdC*
758 *domain-containing protein-like*; *zgc:174917*: phytanoyl-CoA dioxygenase domain-containing
759 protein 1-like; *si:dkey-247k7.2*: carboxypepD reg-like domain-containing protein-like; *si:dkey-*

760 33c14.3 and cr926130.2: uncharacterised lincRNAs; cr855311.1: uncharacterised non-coding
761 RNA. See also **Tables S1,2** for the extended gene lists and **Fig. S2** for in-depth exploration
762 of the data.

763

764 **Figure 3. *S. sonnei* virulence depends on its O-antigen**

765 **A,B. Virulence of *S. sonnei* depends on its virulence plasmid.** Survival curves (A) and
766 Log₁₀-transformed CFU counts (B) of larvae injected in the HBV with *S. sonnei* -pSS (grey),
767 $\Delta mxid$ (blue) or WT (red) strains. Experiments are cumulative of 3 biological replicates. In B,
768 full symbols represent live larvae and empty symbols represent larvae that at the plating
769 timepoint had died within the last 16 hours. Statistics: Log-rank (Mantel-Cox) test (A); one-
770 way ANOVA with Sidak's correction on Log₁₀-transformed data (B); ns, non-significant;
771 **p<0.0021; ****p<0.0001.

772 **C,D. Virulence of *S. sonnei* depends on its O-antigen.** Survival curves (C) and Log₁₀-
773 transformed CFU counts (D) of larvae injected in the HBV with *S. sonnei* ΔO -Ag (blue) or WT
774 (red) strains. Experiments are cumulative of 3 biological replicates. In D, full symbols represent
775 live larvae and empty symbols represent larvae that at the plating timepoint had died within
776 the last 16 hours. Statistics: Log-rank (Mantel-Cox) test (C); unpaired t-test on Log₁₀-
777 transformed data (B); ****p<0.0001.

778

779 **Figure 4. *S. sonnei* O-antigen can counteract clearance by zebrafish neutrophils**

780 **A,B. Macrophages and neutrophils are recruited to *S. sonnei* in vivo.** Larvae of the
781 *Tg(mpeg1:Gal4-FF)^{gl25}*/*Tg(UAS-E1b:nfsB.mCherry)^{c264}* strain (labelling macrophages, A) or of
782 the *Tg(lyz:dsRed)^{nz50}* strain (labelling neutrophils, B) were injected with PBS (blue) or *S.*
783 *sonnei* (red) in the HBV. Recruitment was quantified from images at 6 hpi. Experiments are
784 cumulative of 3 biological replicates. Statistics: two-tailed Mann-Whitney test; ns, non-
785 significant; ****p<0.0001.

786 **C,D. Macrophage ablation does not increase susceptibility to *S. sonnei*.** Survival curves
787 (C) and Log₁₀-transformed CFU counts (D) of *Tg(mpeg1:Gal4-FF)^{gl25}*/*Tg(UAS-*

788 *E1b:nfsB.mCherry*)^{c264} larvae which were treated with either Metronidazole (Mtz, macrophage
789 ablated group, blue) or control DMSO vehicle (DMSO, red) prior to infection in the HBV with
790 *S. sonnei*. Experiments are cumulative of 3 biological replicates. In D, full symbols represent
791 live larvae and empty symbols represent larvae that at the plating timepoint had died within
792 the last 16 hours. Statistics: Log-rank (Mantel-Cox) test (C); unpaired t-test on Log₁₀-
793 transformed data (D); ns, non-significant.

794 **E,F. *pu.1* morpholino knockdown increases susceptibility to *S. sonnei*.** Survival curves
795 (E) and Log₁₀-transformed CFU counts (F) of *pu.1* morphant (blue) or control (red) larvae
796 infected in the HBV with *S. sonnei*. Experiments are cumulative of 3 biological replicates. In
797 F, full symbols represent live larvae and empty symbols represent larvae that at the plating
798 timepoint had died within the last 16 hours. Statistics: Log-rank (Mantel-Cox) test (E); unpaired
799 t-test on Log₁₀-transformed data (F); ns, non-significant; ****p<0.0001.

800 **G,H. Virulence of Δ O-Ag *S. sonnei* can be observed in *pu.1* morphants.** Survival curves
801 (G) and Log₁₀-transformed CFU counts (H) of *pu.1* morphant (blue) or control (red) larvae
802 infected in the HBV with Δ O-Ag *S. sonnei*. To allow full ablation of immune cells by morpholino
803 knockdown, infections were performed at 30 hours post-fertilisation (hpf). Experiments are
804 cumulative of 3 biological replicates. In H, full symbols represent live larvae and empty
805 symbols represent larvae that at the plating timepoint had died within the last 16 hours.
806 Statistics: Log-rank (Mantel-Cox) test (G); unpaired t-test on Log₁₀-transformed data (H);
807 ****p<0.0001.

808

809 **Figure 5. *S. sonnei* can resist phagolysosome acidification and promote neutrophil cell
810 death in an O-antigen-dependent manner**

811 **A. *S. sonnei* is collected by neutrophils in large phagosomes.** Larvae of the
812 *Tg(lyz:dsRed*)^{nz50} strain (labelling neutrophils) were injected in the HBV with WT GFP-*S.*
813 *sonnei*. Image was taken at 3 hpi. Scale bar = 50 μ m.

814 **B. *S. sonnei* is acidified in immune cell phagosomes.** Larvae were injected in the HBV
815 with WT GFP-*S. sonnei* which was also stained with pHrodo, a pH-sensitive dye that turns red

816 in acidic environments. Dashed lines highlight the outline of individual phagocytes. Image
817 taken at 4 hpi. Scale bar = 20 μ m.

818 **C,D. *S. sonnei* O-antigen contributes to acid tolerance *in vitro*.** Growth curves of Δ O-Ag
819 (blue) or WT (red) *S. sonnei*, cultured in tryptic soy broth adjusted to pH = 5 (C) or 7 (D).
820 Statistics: unpaired t-test at the latest timepoint; **p<0.0021.

821 **E,F. *S. sonnei* requires the O-antigen to survive in phagosomes.** Transmission electron
822 micrographs of infected phagocytes from zebrafish larvae at 3 hpi with WT (E) or with Δ O-Ag
823 (F) *S. sonnei*. E shows an intact phagocyte and *S. sonnei* residing within a phagosome (arrow
824 points at phagosomal membrane). F shows that Δ O-Ag *S. sonnei* bacteria being degraded by
825 a phagocyte (arrows point at region of major loss of bacterial cell integrity). Scale bars = 3 μ m
826 (E); 2 μ m (F).

827 **G-J. The O-antigen is required for *S. sonnei*-mediated killing of neutrophils.**
828 Representative micrographs of larvae of the *Tg(lyz:dsRed)*^{nz50} strain injected in the HBV with
829 PBS (G), GFP- Δ O-Ag (H) or WT (I) *S. sonnei* at 6 hpi and quantification of total neutrophil
830 number at 6 and 24 hpi (J). Statistics: Kruskal-Wallis test with Dunn's correction; ns, non-
831 significant; **p<0.0021; ****p<0.0001. Scale bars = 250 μ m.

832

833 **Figure 6. Phagolysosome acidification controls *S. sonnei* clearance by zebrafish and**
834 **human neutrophils**

835 **A,B. Baflomycin treatment increases susceptibility to WT and Δ O-Ag *S. sonnei*.** Survival
836 curves of larvae treated with control DMSO vehicle (blue) or baflomycin (red) upon infection
837 in the HBV with WT (A) or Δ O-Ag (B) *S. sonnei*. Experiments are cumulative of 3 biological
838 replicates. Bacterial input: ~7000 CFU. Statistics: Log-rank (Mantel-Cox) test; ****p<0.0001.

839 **C. ATP injections protect against *S. sonnei* infection.** Survival curves of larvae injected in
840 the HBV with control water (blue) or ATP (red) 3 hours prior to infection of the same
841 compartment with *S. sonnei*. Experiments are cumulative of 3 biological replicates. Bacterial
842 input: ~7000 CFU. Statistics: Log-rank (Mantel-Cox) test; ****p<0.0001.

843 **D. Bafilomycin treatment and ATP injections counteract each other.** Survival curves of
844 larvae injected in the HBV with ATP 3 hours prior to infection of the same compartment with
845 *S. sonnei* and treatment with control DMSO vehicle (blue) or bafilomycin (red). Experiments
846 are cumulative of 3 biological replicates. Bacterial input: ~7000 CFU. Statistics: Log-rank
847 (Mantel-Cox) test; ****p<0.0001.

848 **E,F. *S. sonnei* O-Ag is required to counteract acidification-mediated clearance by**
849 **human neutrophils.** Δ O-Ag (grey), complemented strain (Δ O-Ag $^{+pSSO-Ag}$, blue) or WT (red)
850 *S. sonnei* were incubated with peripheral human neutrophils and exposed to DMSO (vehicle
851 control treatment, E) or Bafilomycin (F). Difference in bacterial killing was quantified by plating
852 from lysates of infected neutrophils at 1 hpi. Experiments are cumulative of 3 biological
853 replicates from 3 independent donors. Statistics: one-way ANOVA with Sidak's correction; ns,
854 non-significant; *p<0.0332; **p<0.0021.

855 **G,H. Model of *S. sonnei* O-antigen counteracting neutrophils *in vivo*.** Upon phagocytosis
856 of WT *S. sonnei* (green), zebrafish neutrophils (red) rapidly acidify phagolysosomes containing
857 bacteria. However, *S. sonnei* can tolerate this environment because of its O-antigen. *S. sonnei*
858 replication leads to neutrophil and host death (G). *S. sonnei* without O-antigen fail to
859 counteract acidification of neutrophil phagolysosomes. In this case, neutrophils clear infection
860 and the host survives (H).

861

862 **Figure 7. Innate immunity can be trained to control *S. sonnei* *in vivo***

863 **A. Model for *S. sonnei* reinfection.** 2 dpf embryos were primed with PBS or a sublethal dose
864 of *S. sonnei*. At 48 hours post primary infection (hp1i), larvae were challenged with a lethal
865 dose of *S. sonnei* and monitored by survival assay for 72 hours post-secondary infection
866 (hp2i).

867 **B,C. Innate immune training to *S. sonnei* is dependent on O-antigen.** Survival curves (B)
868 and Log₁₀-transformed CFU counts (C) of 4 dpf larvae infected in the HBV with lethal dose
869 (~8000 CFU) of mCherry-WT *S. sonnei*. 48 hours prior to infection with lethal dose, embryos

870 were primed by delivering PBS (grey), or a sublethal dose (~80 CFU) of GFP- Δ O-Ag (blue) or
871 GFP-WT (red) *S. sonnei*. Experiments are cumulative of 4 (B) or 3 (C) biological replicates. In
872 C, full symbols represent live larvae and empty symbols represent larvae that at the plating
873 timepoint had died within the last 16 hours. Statistics: Log-rank (Mantel-Cox) test (G);); one-
874 way ANOVA with Sidak's correction on Log₁₀-transformed data (H); ns, non-significant;
875 *p<0.0332; ***p<0.0002; ****p<0.0001.

876

877

878 **Supporting Information Legends**

879 **Figure S1. (Related to Fig. 1) *S. sonnei* is more virulent than *S. flexneri* in a zebrafish
880 infection model**

881 **A,B. Dose response to *S. sonnei* infection.** Survival curves (A) and Log₁₀-transformed CFU
882 counts (B) of larvae injected in the HBV with increasing doses of *S. sonnei*. ~200 CFU range:
883 100-300 CFU (grey); ~600 CFU range: 400-700 CFU (blue); ~1500 CFU range: 1000-2000
884 CFU (green); ~5000 CFU: 4000-6000 CFU (red). Experiments are cumulative of 3 biological
885 replicates. In B, full symbols represent live larvae and empty symbols represent larvae that at
886 the plating timepoint had died within the last 16 hours. Statistics: Log-rank (Mantel-Cox) test
887 (A); one-way ANOVA with Sidak's correction on Log₁₀-transformed data (B); ns, non-
888 significant; *p<0.0332; **p<0.0021; ****p<0.0001.

889 **C-F. *S. sonnei* can disseminate from the injection site.** Representative images of three
890 larvae injected in the HBV with ~20000 CFU of GFP-labelled *S. flexneri* (C, compare to **Fig.**
891 **1E,F**). The frequency of larvae with bacterial dissemination out of the HBV at 24 hpi is
892 significantly higher for the *S. sonnei*-infected group when compared to the *S. flexneri* infected
893 group (even when *S. flexneri* input is ~3-fold higher than *S. sonnei* input) (D). Survival curves
894 (E) and Log₁₀-transformed CFU counts (F) of larvae injected in the HBV with ~7000 CFU *S.*
895 *flexneri* (grey), ~20000 CFU of *S. flexneri* (blue) or ~7000 CFU *S. sonnei* (red). Experiments
896 are cumulative of 3 biological replicates. In E, full symbols represent live larvae and empty

897 symbols represent larvae that at the plating timepoint had died within the last 16 hours.
898 Statistics: two-sided *chi*-squared contingency test (D); Log-rank (Mantel-Cox) test (E); one-
899 way ANOVA with Sidak's correction on Log₁₀-transformed data (F); ns, non-significant;
900 **p<0.01; ****p<0.0001. Scale bar = 1 mm.

901 **G,H. *S. sonnei* is more virulent than *S. flexneri* in an intravenous infection model.**
902 Survival curves (G) and Log₁₀-transformed CFU counts (H) of larvae injected intravenously
903 (IV, via the duct of Cuvier) with PBS (grey), *S. flexneri* (blue) or *S. sonnei* (red). Experiments
904 are cumulative of 2 biological replicates. In H, full symbols represent live larvae and empty
905 symbols represent larvae that at the plating timepoint had died within the last 16 hours.
906 Statistics: Log-rank (Mantel-Cox) test (G); unpaired t-test on Log₁₀-transformed data (H); ns,
907 non-significant; ****p<0.0001.

908 **I,J. A clinical isolate of *S. sonnei* is more virulent than a clinical isolate of *S. flexneri*.**
909 Survival curves (I) and Log₁₀-transformed CFU counts (J) of larvae injected in the HBV with
910 *S. flexneri* isolate 2457T (blue) or *S. sonnei* isolate 381 (red). Experiments are cumulative of
911 3 biological replicates. In J, full symbols represent live larvae and empty symbols represent
912 larvae that at the plating timepoint had died within the last 16 hours. Statistics: Log-rank
913 (Mantel-Cox) test (I); unpaired t-test on Log₁₀-transformed data (J); **p<0.0021; ****p<0.0001.

914 **K-N. *S. sonnei* is more virulent than *S. flexneri* at 32.5°C and 37°C.** Survival curves (K,M)
915 and Log₁₀-transformed CFU counts (L,N) of larvae injected in the HBV with *S. flexneri* (blue)
916 or *S. sonnei* (red) at 32.5°C (K,L) or at 37°C (M,N). Experiments are cumulative of 2 biological
917 replicates. In L,N, full symbols represent live larvae and empty symbols represent larvae that
918 at the plating timepoint had died within the last 16 hours. Statistics: Log-rank (Mantel-Cox)
919 test (K,M); unpaired t-test on Log₁₀-transformed data (L,N); ns, non-significant; *p<0.0332;
920 ****p<0.0001.

921

922 **Figure S2. (Related to Fig. 2) Whole animal dual-RNAseq profiling of *S. sonnei* infected**
923 **larvae**

924 **A,B. Principal component analysis (PCA) of *S. sonnei* and zebrafish larvae**
925 **transcriptomes.** Analysis was performed on counts per million (CPM) reads values, using the
926 dedicated PCA tools in R. Individual biological replicates (R1, R2, R3) for control (blue) and
927 infected (red) conditions are reported. % in brackets indicate the variance of dimension
928 explained by each principal component. Plot in A refers to *S. sonnei* genes and plot in B refers
929 to zebrafish genes.

930 **C,D. Boxplots representing the distribution of reads within the RNAseq libraries of each**
931 **individual sample.** Boxplots represent the sample median CPM reads with interquartile
932 range, while whiskers indicate the 2.5-97.5 percentile range. Control samples are indicated in
933 blue and infection samples are indicated in red. Biological replicates (R1, R2, R3) are also
934 indicated. Plot in C refers to *S. sonnei* gene libraries and plot in D refers to zebrafish gene
935 libraries.

936 **E-H. Distribution histograms of significantly differentially expressed genes in *S. sonnei***
937 **and zebrafish larvae during infections.** Each bar represents the number of significantly
938 differentially expressed genes (repressed, blue (E,F); induced, red (G,H)) in each interval of
939 $\text{Log}_2(\text{FC})$. Plots in E,G refer to *S. sonnei* genes, while plots in F,H refer to zebrafish genes.

940 **I. Induction of well established inflammatory markers in the RNAseq transcriptome.**
941 Bars indicate the average CPM reads for representative inflammatory marker. Compare to
942 induction of same genes tested independently by qRT-PCR at the same timepoint in **Fig. 1D**.
943 Statistics: unpaired t-test on Log_2 -transformed data; **p<0.0021; ***p<0.0002; ****p< 0.0001.

944 **J. Pathway enrichment analysis of *S. sonnei* during infection *in vivo*.** Pathway
945 enrichment analysis was performed manually using the top 50 differentially expressed genes.
946 Gene functions were inferred from *E. coli* annotations (accessible via uniprot.org). % are
947 relative to all 50 genes analysed. A variety of stress response processes are induced in *S.*
948 *sonnei* *in vivo* in the zebrafish larvae (i.e. amino acid metabolism, acid resistance systems,
949 purine metabolism and DNA damage repair, regulation of transcription or translation and
950 protection against oxidative stress). Upregulated genes involved in acidic adaptation include
951 GadA, GadB, GadC and their transcriptional regulator GadE (the Gad pathway constitutes a

952 glutamate-dependent system to maintain neutral cytoplasmic pH in acid conditions) [52], as
953 well as HdeA, HdeB and HdeD (the Hde pathway constitutes an acid-induced chaperone
954 system to prevent protein misfolding in acid environment) [53]. In agreement with upregulation
955 of acid resistance, 60% (9/15) of the genes associated with metabolic changes are specifically
956 involved in the biosynthesis of glutamate (essential to fuel the GadA/B/C system) or arginine
957 (shown to activate an arginine-dependent acid resistance system [54]).

958 **K. Pathway enrichment analysis of *S. sonnei*-infected zebrafish larve.** Pathway
959 enrichment analysis was performed using ShinyGO v0.60
960 (<http://bioinformatics.sdsu.edu/go/>). % are relative to all the genes bioinformatically
961 annotated to the pathway of interest. A variety of immune-related processes are induced in
962 zebrafish larvae in response to *S. sonnei* infection, including leukocyte (especially neutrophil)
963 chemotaxis, response to cytokines and inflammation.

964

965 **Figure S3. (Related to Fig. 3) *S. sonnei* virulence depends on its O-antigen**

966 **A,B. Schematic of *S. sonnei* and *S. flexneri*.** Both *S. flexneri* and *S. sonnei* virulence
967 plasmid encodes a type 3 secretion system (T3SS). However, differently than *S. flexneri*, *S.*
968 *sonnei* virulence plasmid (pSS) encodes genes for the biosynthesis of a capsule and O-
969 antigen (O-Ag) non-homologous to those of other *Escherichia* and *Shigella* species. *S. sonnei*
970 additionally encodes a type 6 secretion system (T6SS) on the bacterial chromosome. The
971 schematic in B also reports (in grey and between brackets) the name of the mutants used in
972 the study.

973 **C,D. Virulence of *S. sonnei* in zebrafish does not depend on the T6SS or capsule.**
974 Survival curves (C) and Log₁₀-transformed CFU counts (D) of larvae injected in the HBV with
975 *S. sonnei* Δ tssb (grey), Δ g4c (blue), or WT (red) strains. Experiments are cumulative of 4 (C)
976 or 3 (D) biological replicates. In D, full symbols represent live larvae and empty symbols
977 represent larvae that at the plating timepoint had died within the last 16 hours. Statistics: Log-
978 rank (Mantel-Cox) test (C); one-way ANOVA with Sidak's correction on Log₁₀-transformed
979 data (D); ns, non-significant.

980 **E. S. sonnei virulence plasmid is maintained *in vivo* in zebrafish at 28.5°C.** Larvae were
981 injected with 1nl (~7000 CFU) in the HBV with *S. flexneri* (blue) or *S. sonnei* (red) for 24 h at
982 28.5°C. Control bacteria (TSA plates) were spotted onto tryptic soy agar plates (10 μ l of the
983 bacterial inoculum/spot) and also grown for 24 h at 28.5°C. Bacteria were then harvested from
984 larvae or plates and grown on Congo-Red plates at 37°C to quantify colonies that lost the
985 virulence plasmid. Experiments are cumulative of 2 biological replicates. Statistics: one-way
986 ANOVA with Sidak's correction; ns, non-significant; *p<0.0332; **p<0.0021.

987 **F. Comparison of *S. sonnei* and *S. flexneri* O-antigen.** *S. sonnei* 53G O-antigen has a
988 unique sugar composition compared to the O-antigen of *S. flexneri* M90T. Figure legend
989 abbreviations: AN: 2-Acetamido-2-deoxy-L-altruronic acid (L-AltNAc); FN: 2-Acetamido-4-
990 amino-2,4-dideoxy-D-fucose (D-FucNAc); GN: 2-Acetamido-2-deoxy-D-glucose (D-GlcNAc);
991 R: L-Rhamnose (L-Rha); G: D-Glucose (D-Glc); Ac: O-acetyl. Adapted from [55].

992 **G. Induction of the O-antigen chain length determinant protein wzzB *in vivo*.** Dual-
993 RNAseq profiling shows that the *wzzB* is significantly upregulated in *S. sonnei* infected
994 zebrafish. Bars indicate the average CPM reads. Statistics: unpaired t-test on Log₂-
995 transformed data; ***p<0.0002.

996

997 **Figure S4. (related to Fig. 4) *S. sonnei* O-antigen can counteract clearance by zebrafish
998 neutrophils**

999 **A-C. Chemical ablation of macrophages.** Representative micrographs (A,B) and
1000 quantification (C) of *Tg(mpeg1:Gal4-FF)^{gl25}/Tg(UAS-E1b:nfsB.mCherry)^{c264}* larvae which were
1001 treated with either Metronidazole (Mtz, macrophage ablated group, blue) or control DMSO
1002 vehicle (DMSO, red) prior to infection in the HBV with *S. sonnei*. Experiments are cumulative
1003 of 2 biological replicates. Scale bars = 250 μ m.

1004 **D,E. Macrophage ablation increases susceptibility to *S. flexneri*.** Survival curves (D) and
1005 Log₁₀-transformed CFU counts (E) of *Tg(mpeg1:Gal4-FF)^{gl25}/Tg(UAS-E1b:nfsB.mCherry)^{c264}*
1006 larvae which were treated with either Metronidazole (Mtz, macrophage ablated group, blue)
1007 or control DMSO vehicle (DMSO, red) prior to infection in the HBV with *S. flexneri*.

1008 Experiments are cumulative of 3 biological replicates. In E, full symbols represent live larvae
1009 and empty symbols represent larvae that at the plating timepoint had died within the last 16
1010 hours. Statistics: Log-rank (Mantel-Cox) test (D); unpaired t-test on Log₁₀-transformed data
1011 (E); ns, non-significant; *p<0.0332.

1012 **F, G. *pu.1* morpholino knockdown increases susceptibility to *S. sonnei* when infections
1013 are performed at 30 hpf.** Survival curves (F) and Log₁₀-transformed CFU counts (G) of *pu.1*
1014 morphant (blue) or control (red) larvae infected in the HBV with WT *S. sonnei*. Experiments
1015 are cumulative of 3 biological replicates. In G, full symbols represent live larvae and empty
1016 symbols represent larvae that at the plating timepoint had died within the last 16 hours. To
1017 allow full ablation of immune cells by morpholino knockdown, infections are performed at 30
1018 hpf. Statistics: Log-rank (Mantel-Cox) test (F); unpaired t-test on Log₁₀-transformed data (G);
1019 ns, non-significant; ****p<0.0001.

1020

1021 **Figure S5. (related to Fig. 5) *S. sonnei* can resist phagolysosome acidification and
1022 promote neutrophil cell death in an O-antigen-dependent manner**

1023 **A, B. *S. sonnei* O-antigen contributes to acid tolerance *in vitro*.** Growth curves of ΔO-Ag
1024 (blue) or WT (red) *S. sonnei*, cultured in tryptic soy broth adjusted to pH = 4 (A) or 6 (B).
1025 Statistics: unpaired t-test at the latest timepoint; ns, non-significant.

1026 **C. *S. sonnei* can replicate within phagosomes.** Transmission electron micrograph of an
1027 infected phagocyte from zebrafish larvae at 3 hpi with WT *S. sonnei*, showing a dividing *S.*
1028 *sonnei* cell. Scale bar = 4 μm.

1029 **D. *S. sonnei* infection of zebrafish cell promotes morphological features of necrosis.**
1030 Transmission electron micrograph of an infected neutrophil from a zebrafish larva at 3 hpi with
1031 WT *S. sonnei*, showing signs of necrotic cell death (arrowheads point at area of extranuclear
1032 chromatin degradation). Scale bar = 4 μm.

1033 **E. Pharmacological inhibition of necroptosis and/or apoptosis/pyroptosis does not
1034 protect zebrafish larvae.** Survival curves of larvae which were treated with Necrostatin-1
1035 (grey), Necrostatin-5 (blue), Q-VD-OPh (green), Necrostatin-1 + Q-VD-OPh (red) or control

1036 DMSO vehicle (black) upon infection in the HBV with *S. sonnei*. Experiments are cumulative
1037 of 3 biological replicates. Bacterial input: ~7000 CFU. Statistics: Log-rank (Mantel-Cox) test;
1038 ns, non-significant. Scale bar = 4 μ m.

1039

1040 **Figure S6. (related to Fig. 7) Innate immunity can be trained to control *S. sonnei* in vivo**

1041 **A,B. Response of 2dpf zebrafish embryos to sublethal dose (~80 CFU) of *S. sonnei*.**

1042 Approximately 80% of WT GFP-*S. sonnei* injected embryos (and 100% of Δ O-Ag GFP-*S.*

1043 *sonnei* control/clear infection (no detectable bacteria by fluorescence microscopy) by 48 hpi

1044 (A). Log₁₀-transformed CFU counts from controller larvae (no detectable bacteria by

1045 fluorescence microscopy) infected in the HBV with GFP- Δ O-Ag (blue) or WT (red) *S. sonnei*.

1046 Prior to receiving the secondary lethal dose (~8000 CFU) of mCherry-*S. sonnei*, ~80% of WT

1047 GFP-*S. sonnei* injected controllers (and 100% of Δ O-Ag GFP-*S. sonnei* injected controllers)

1048 cleared the primary infection. Experiments are cumulative of 4 (A) or 3 (B) biological replicates.

1049 Statistics in A: two-sided *chi*-square contingency test.

1050

1051 **Table S1. Differentially expressed *S. sonnei* genes and pathogen pathway enrichment**
1052 **analysis *in vivo*.**

1053

1054 **Table S2. Differentially expressed zebrafish genes and host pathway enrichment**
1055 **analysis in response to *S. sonnei* infection.**

1056


1057 **Table S3. Bacterial strains used in this study.**

1058


1059 **Table S4. Primers and morpholinos used in this study.**

Figure 1. *S. sonnei* is more virulent than *S. flexneri* in a zebrafish infection model


A




B




C 6 hpi



D 24 hpi



E



F





Figure 1

Figure 2. Whole animal dual-RNAseq profiling of *S. sonnei* infected larvae


A



bioRxiv preprint doi: <https://doi.org/10.1101/719781>; this version posted July 30, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.

B


Differentially expressed *S. sonnei* genes



D


S. sonnei in vitro

S. sonnei in vivo



C

Differentially expressed zebrafish genes



E

PBS injected larvae

S. sonnei infected larvae






Figure 2

Figure 3. *S. sonnei* virulence depends on its O-antigen


A



B



C



D






Figure 3

Figure 4. *S. sonnei* O-antigen can counteract clearance by zebrafish neutrophils


A




B




C




D




E



F



G 30 hpf embryos



H 30 hpf embryos




Figure 4

Figure 5. *S. sonnei* can resist phagolysosome acidification and promote neutrophil cell death in an O-antigen-dependent manner




Figure 5

Figure 6. Phagolysosome acidification controls *S. sonnei* clearance by zebrafish and human neutrophils






Figure 6

Figure 7. Innate immunity can be trained to control *S. sonnei* in vivo

A



B



bioRxiv preprint doi: <https://doi.org/10.1101/719781>; this version posted July 30, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license.

C




Figure 7